McDonald succeeds Lafley as P&G chairman: A.G. Lafley hands over the reins as Procter & Gamble chairman to Bob McDonald on Jan. 1, 2010 - almost two months before he will retire. The move is part of a phased-in leadership transition that began in June when Lafley passed the president and CEO baton to McDonald (1"The Tan Sheet" June 15, 2009). In the 10 years Lafley was president and CEO, Cincinnati-based P&G doubled its sales and grew its portfolio of billion-dollar brands from 10 to 22, according to a Dec. 8 release. ... WellPoint's Braly joins board: In a same-day release, P&G says it appointed WellPoint President and CEO Angela F. Braly to its board effective immediately. WellPoint, a health benefits provider with 34 million members, has initiated coverage for OTC products in some areas (2"The Tan Sheet" May 26, 2008)
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.
